13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q1 2021. See the latest, Q2 2026 →
Reported value
$2.48B
+19% on the quarter before
Positions
32
4 new · 3 sold out
Top 10
85.7%
of the value
Est. gain
+$134.5M
on stocks held all quarter
Est. return
+8.6%
on those stocks since Q4 2020
Positions as of Mar 31, 2021, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2020. Striped tiles are options.
Largest buys
Since Q4 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Oscar Health Inc~$646.3MNew · 0.0% → 26.1%+24,042,864 shares
- Sana Biotechnology Inc~$94.1MNew · 0.0% → 3.8%+2,812,500 shares
- Clover Health Investments Co~$31.1MNew · 0.0% → 1.3%+4,113,742 shares
- Decibel Therapeutics Inc~$18.6MNew · 0.0% → 0.7%+1,636,258 shares
Largest sells
Since Q4 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Lyft Inc~$325.3MCut · 27.3% → 16.4%−5,149,539 shares
- Twilio~$160.9MCut · 7.7% → 0.1%−472,083 shares
- Lemonade~$60.3MCut · 4.8% → 0.7%−647,045 shares
- Mohawk Group Hldgs Inc~$10.1MSold out · 0.5% → 0.0%−586,327 shares
- Arcus Biosciences Inc~$9.2MCut · 6.3% → 5.3%−326,438 shares
- Relay Therapeutics Inc~$8.1MCut · 3.6% → 2.2%−233,004 shares
- Cloudera Inc~$5.9MSold out · 0.3% → 0.0%−427,710 shares
- Beam Therapeutics Inc~$1.8MCut · 2.6% → 2.1%−22,899 shares
- Dropbox Inc~$289,000Sold out · 0.0% → 0.0%−13,033 shares
Holdings
As of Mar 31, 2021. Changes are in shares against Dec 31, 2020, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oscar Health IncCL A · shares New | 26.1% | $646.3M | — | ||||||||
| Lyft IncCL A COM · shares −45% · price +28.6% | 16.4% | $405.7M | +$90.2M | ||||||||
| Dexcom IncCOM · shares 0% · price −2.8% | 11.7% | $289.6M | −$8.3M | ||||||||
| Desktop Metal Inc.COM CL A · shares 0% · price −13.4% | 8.6% | $213.1M | −$32.9M | ||||||||
| Arcus Biosciences IncCOM · shares −6.5% · price +8.2% | 5.3% | $132.6M | +$10.0M | ||||||||
| AirbnbCOM CL A · shares 0% · price +28.0% | 5.2% | $130.0M | +$28.5M | ||||||||
| UpstartCOM · shares 0% · price +216.2% | 4.3% | $107.3M | +$73.3M | ||||||||
| Sana Biotechnology IncCOM · shares New | 3.8% | $94.1M | — | ||||||||
| Relay Therapeutics IncCOM · shares −13% · price −16.8% | 2.2% | $54.2M | −$11.0M | ||||||||
| Slack Technologies Inc.COM CL A · shares 0% · price −3.8% | 2.1% | $52.8M | −$2.1M | ||||||||
| Beam Therapeutics IncCOM · shares −3.5% · price −2.0% | 2.1% | $51.3M | −$1.0M | ||||||||
| Kronos Bio IncCOM · shares 0% · price −2.0% | 1.7% | $42.1M | −$863,000 | ||||||||
| Magenta Therapeutics IncCOM · shares 0% · price +51.0% | 1.6% | $39.5M | +$13.4M | ||||||||
| Clover Health Investments CoCOM CL A · shares New | 1.3% | $31.1M | — | ||||||||
| Opendoor Technologies IncCOM · shares 0% · price −6.8% | 1.1% | $26.5M | −$1.9M | ||||||||
| Decibel Therapeutics IncCOM · shares New | 0.75% | $18.6M | — | ||||||||
| Rapt Therapeutics IncCOM · shares 0% · price +12.4% | 0.74% | $18.5M | +$2.0M | ||||||||
| Ideaya Biosciences IncCOM · shares 0% · price +67.9% | 0.71% | $17.7M | +$7.2M | ||||||||
| LemonadeCOM · shares −78% · price −24.0% | 0.67% | $16.5M | −$5.2M | ||||||||
| Spero Therapeutics IncCOM · shares 0% · price −24.1% | 0.53% | $13.1M | −$4.2M | ||||||||
| Taysha Gene Therapies IncCOM SHS · shares 0% · price −23.5% | 0.52% | $13.0M | −$4.0M | ||||||||
| Sqz Biotechnologies CoCOM · shares 0% · price −52.8% | 0.46% | $11.4M | −$12.7M | ||||||||
| Evelo Biosciences IncCOM · shares 0% · price −11.5% | 0.46% | $11.3M | −$1.5M | ||||||||
| Fulcrum Therapeutics IncCOM · shares 0% · price +0.6% | 0.32% | $8.0M | +$47,000 | ||||||||
| Cortexyme IncCOM · shares 0% · price +29.7% | 0.27% | $6.8M | +$1.6M | ||||||||
| Total · 32 positions | 100% | $2.48B | +$134.5M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2020 to Q1 2021: 28 stocks held throughout, up $134.5M (+8.6%).
- Lyft Inc+$90.2M+29%
- Upstart+$73.3M+216%
- Airbnb+$28.5M+28%
- Magenta Therapeutics Inc+$13.4M+51%
- Arcus Biosciences Inc+$10.0M+8%
- Lemonade−$5.2M−24%
- Dexcom Inc−$8.3M−3%
- Relay Therapeutics Inc−$11.0M−17%
- Sqz Biotechnologies Co−$12.7M−53%
- Desktop Metal Inc.−$32.9M−13%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |